Evidence map›Paper›PMID 41324162›Full record

ArticleThe Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology2026

Identification of novel molecular subtypes in ovarian cancer

Mengyu Lyu, Miao Qiu

Abstract read
In one paragraph

Article in The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Mengyu LyuPharmacy Department, Shaoxing Second Hospital, Yuecheng District, Shaoxing 312000, Zhejiang, China.
Miao QiuDepartment of Tumor Radiotherapy, Shaoxing Second Hospital, Yuecheng District, Shaoxing 312000, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer (OV) remains a leading cause of gynecologic cancer mortality, this is primarily attributed to the absence of early symptoms and reliable diagnostic biomarkers. Recent studies suggest that zinc dysregulation reshapes the tumor microenvironment, impairs immune surveillance, and promotes tumor progression. However, the prognostic implications of zinc homeostasis-related genes in OV remain poorly understood. Patients with OV were stratified into molecular subtypes based on the expression profiles of prognostic zinc homeostasis-related genes. Differential gene expression analysis was conducted using the limma package. Subsequently, we constructed a zinc homeostasis-based risk score model employing univariate Cox regression, least absolute shrinkage and selection operator regression, and multivariate Cox regression analyses. The prognostic model was validated using external datasets. Additionally, immune cell infiltration and drug sensitivity analyses were conducted to evaluate the clinical relevance of the model. Two molecular subtypes of OV were identified, each associated with distinct biological pathways. A prognostic model comprising four zinc homeostasis-related genes was developed, demonstrating robust predictive capability for overall survival and significant correlation with immune cell infiltration patterns. Drug sensitivity analysis revealed potential therapeutic targets and candidate drugs, offering insights for OV treatment strategies. This study identifies novel OV subtypes driven by zinc homeostasisrelated genes, providing insights into the genetic heterogeneity, immune landscape, and therapeutic strategies of OV. The developed prognostic model and identified candidate therapeutic agents offer valuable references for personalized treatment approaches in OV.

Indexed as

Ovarian cancerPrognosisTumor microenvironmentZinc homeostasis

Identifiers

PMID41324162
PMCPMC12954785

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.